Repurposing drugs for Triple negative Breast cancer: dupe of High-end Chemotherapeutics
1Vaishnavi S. Patil* and 2V. V. Vaidya
1M. Pharmacy Pharmaceutics, 2. PhD Dr. D. Y. Patil College of Pharmacy, Dr. D. Y. Patil Educational Complex, Akurdi, Pune-411044 India CorrespondingAuthor’s e-mail*: - patilvaishnavi4049@gmail.com
ABSTRACT
One of the most prevalent types of cancer is breast cancer. It is commonly occurring type of cancer that can account for nearly 11% of all cancer cases. Breast cancer is further classified into several categories on the basis of histology or molecular subtypes. Molecular subtypes of breast cancer include ‘Triple-Negative Breast Cancer’(TNBC). The most severe type of breast cancer, triple-negative breast cancer (TNBC) has a significant recurrence, metastasis and mortalityrate. Oestrogen receptors (ERs), progesterone receptors (PRs) and human epidermal growth factor receptors type 2 (HER2s) are all negativelyexpressed by TNBC. Existing treatments that are generally deployed includes chemotherapy, immunotherapy, radiotherapyand surgery. Along with major side effects the limitations of these therapies are- lack of therapeutic target, chemoresistance and poor prognosis. This review will focus on commonly incorporated conventional treatments and challenges faced. It will highlight the cost effective and novel perspective of drug repurposing. Along with this it will also summarise the futuristic approach of drug repurposing with exclusive examples of repurposed drug for the treatment of TNBC. The generally repurposed drugs are antidiabetic, beta-blockers, NSAIDs.